Pivot X, Manikhas AG, Shamrai V, Dzagnidze G, et al. Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting. BMC Cancer 2023;23:112.
PMID: 36721174